A stochastic whole-body physiologically based pharmacokinetic model to assess the impact of inter-individual variability on tissue dosimetry over the human lifespan

Regulatory Toxicology and Pharmacology

Volumn 57, Issue 1, 2010, Pages 103-116

  Beaudouin, Rémy ^a   Micallef, Sandrine ^a   Brochot, Céline ^a  

^a INSTITUT NATIONAL DE L ENVIRONNEMENT INDUSTRIEL ET DES RISQUES INERIS   (France)

Author keywords

Advanced age; Children; Gestation; Inter individual variability; PBPK model

Indexed keywords

1,3 BUTADIENE; 2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; XENOBIOTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BODY BURDEN; CHILD; CONTROLLED STUDY; DOSIMETRY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; INFANT; LIFESPAN; LONG TERM EXPOSURE; MALE; PREDICTION; PRIORITY JOURNAL; PROBABILITY; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SIMULATION; STOCHASTIC MODEL; TISSUE DISTRIBUTION; TOXICOKINETICS;

AGING; BODY BURDEN; BODY WEIGHT; BUTADIENES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; ORGAN SIZE; PHYSIOLOGICAL PHENOMENA; STOCHASTIC PROCESSES; TETRACHLORODIBENZODIOXIN; TIME FACTORS; TISSUE DISTRIBUTION; XENOBIOTICS;

EID: 77952110779     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2010.01.005     Document Type: Article

References (65)

1. Altman, P.L., Dittmer, D.S., 1962. Growth, including reproduction and morphological development. Federation of American Societies for Experimental Biology, Washington, DC.
2. Andersen M.E. Physiological modelling of organic compounds. The Annals of Occupational Hygiene 1991, 35:309-321.
3. Andersen M.E., Dennison J.E. Toxicokinetic models: where we've been and where we need to go!. Human and Ecological Risk Assessment 2002, 8:1375-1395.
4. Barton H.A., et al. Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation. Toxicological Sciences 2007, 99:395-402.
5. Beaudouin R., et al. Selecting parameters for calibration via sensitivity analysis: an individual-based model of mosquitofish population dynamics. Ecological Modelling 2008, 218:29-48.
6. Bois F.Y., Maszle D. MCSim: a simulation program. Journal of Statistical Software 1997, 2(9). Available from: (software available from: www.toxi.ineris.fr).
7. Brochot C., Bois F.Y. Use of a chemical probe to increase safety for human volunteers in toxicokinetic studies. Risk Analysis 2005, 25:1559-1571.
8. Brochot C., et al. Development of a physiologically based toxicokinetic model for butadiene and four major metabolites in humans: global sensitivity analysis for experimental design issues. Chemico-Biological Interactions 2007, 167:168-183.
9. Clewell H.J. The application of physiologically based pharmacokinetic modeling in human health risk assessment of hazardous substances. Toxicology Letters 1995, 79:207-217.
10. Clewell H.J., Andersen M.E. Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk. Toxicology 1996, 111:315-329.
11. Clewell H.J., et al. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicological Sciences 2004, 79:381-393.
12. Clewell H.J., et al. Quantitative interpretation of human biomonitoring data. Toxicology and Applied Pharmacology 2008, 231:122-133.
13. Dollard, G.J. et al., 2001. Ambient concentrations of 1,3-butadiene in the UK. In: 38th European Congress of Toxicology, London, England, pp. 177-206.
14. d'Yvoire M.B., et al. Physiologically-based kinetic modelling (PBK modelling): meeting the 3Rs agenda. ATLA - Alternatives to Laboratory Animals 2007, 35:661-671.
15. Edginton A.N., et al. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clinical Pharmacokinetics 2006, 45:1013-1034.
16. Elfarra A.A., et al. Biochemistry of 1,3-butadiene metabolism and its relevance to 1,3-butadiene-induced carcinogenicity. Toxicology 1996, 113:23-30.
17. Emond C., et al. Physiologically based pharmacokinetic model for developmental exposures to TCDD in the rat. Toxicological Sciences 2004, 80:115-133.
18. Fajen J.M., et al. Occupational exposure of workers to 1,3-butadiene. Environmental Health Perspectives 1990, 86:11-18.
19. Faulkner J.A., et al. Age-related changes in the structure and function of skeletal muscles. Clinical and Experimental Pharmacology and Physiology 2007, 34:1091-1096.
20. Fürst P., et al. PCDD and PCDF levels in human milk - dependence on the period of lactation. Chemosphere 1989, 18:439-444.
21. Gentry P.R., et al. Application of a physiologically based pharmacokinetic model for isopropanol in the derivation of a reference dose and reference concentration. Regulatory Toxicology and Pharmacology 2002, 36:51-68.
22. Gentry P.R., et al. Application of a physiologically based pharmacokinetic model for reference dose and reference concentration estimation for acetone. Journal of Toxicology and Environmental Health - Part A 2003, 66:2209-2225.
23. Gentry P.R., et al. Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation. Regulatory Toxicology and Pharmacology 2003, 38:1-16.
24. Grant, R.L. et al., 2005. Spatial and temporal trend evaluation of ambient concentrations of 1,3-butadiene and chloroprene in Texas. In: International Symposium on the Evaluation of Butadiene and Chloroprene Health Risks, Charleston, SC, pp. 44-51.
25. Haddad S., et al. Characterization of age-related changes in body weight and organ weights from birth to adolescence in humans. Journal of Toxicology and Environmental Health - Part A 2001, 64:453-464.
26. Hays S.M., et al. Biomonitoring equivalents: a screening approach for interpreting biomonitoring results from a public health risk perspective. Regulatory Toxicology and Pharmacology 2007, 47:96-109.
27. International Commission on Radiological Protection, 2002. Basic anatomical and physiological data for use in radiological protection: reference values. J. Valentin, Stockholm.
28. Johnson T.N., et al. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clinical Pharmacokinetics 2006, 45:931-956.
29. Kerger B.D., et al. Age- and concentration-dependent elimination half-life of 2,3,7,8-tetrachlorodibenzo-p-dioxin in Seveso children. Environmental Health Perspectives 2006, 114:1596-1602.
30. Koppikar, A.M., 2001. Future research needs for the health assessment of 1,3-butadiene. In: 38th European Congress of Toxicology, London, England, pp. 629-636.
31. Kreuzer P.E., et al. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and congeners in infants. A toxicokinetic model of human lifetime body burden by TCDD with special emphasis on its uptake by nutrition. Archives of Toxicology 1997, 71:383-400.
32. Lexell J., et al. What is the cause of the aging atrophy - total number, size and proportion of different fiber types studied in whole vastus lateralis muscle from 15-year-old to 83-year-old men. Journal of the Neurological Sciences 1988, 84:275-294.
33. Liao K.H., et al. Development of a screening approach to interpret human biomonitoring data on volatile organic compounds: reverse dosimetry on biomonitoring data for trichloroethylene. Risk Analysis 2007, 27:1223-1236.
34. Lin Y.S., et al. Human physiologic factors in respiratory uptake of 1,3-butadiene. Environmental Health Perspectives 2001, 109:921-926.
35. Liu, Y. et al., 2004. Distributions and source apportionment of ambient volatile organic compounds in Beijing city, China. In: 2nd International Conference on Environmental Concerns, Xiamen, People's Republic of China, pp. 1843-1860.
36. Loizou G., et al. Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps. Regulatory Toxicology and Pharmacology 2008, 50:400-411.
37. Luecke R.H., et al. A Physiologically-based pharmacokinetic computer-model for human-pregnancy. Teratology 1994, 49:90-103.
38. Luisada A.A., et al. Changes of cardiac-output caused by aging - an impedance cardiographic study. Angiology 1980, 31:75-81.
39. Macaluso M., et al. Historical estimation of exposure to 1,3-butadiene, styrene, and dimethyldithiocarbamate among synthetic rubber workers. Journal of Occupational and Environmental Hygiene 2004, 1:371-390.
40. Maruyama, W. et al., 2001. Simulation of dioxin accumulation in human tissues and analysis of reproductive risk. In: 4th International Workshop on Risk Evaluation and Management of Chemicals, Yokohama, Japan, pp. 301-313.
41. Mezzetti M., et al. A Bayesian compartmental model for the evaluation of 1,3-butadiene metabolism. Journal of the Royal Statistical Society Series C - Applied Statistics 2003, 52:291-305.
42. Milbrath M.O., et al. Apparent Half-Lives of Dioxins, Furans, and Polychlorinated Biphenyls as a Function of Age, Body Fat, Smoking Status, and Breast-Feeding. Environmental Health Perspectives 2009, 117:417-425.
43. Nakano S., et al. Maternal-fetal distribution and transfer of dioxins in pregnant women in Japan, and attempts to reduce maternal transfer with Chlorella (Chlorella pyrenoidosa) supplements. Chemosphere 2005, 61:1244-1255.
44. National Health and Nutrition Examination Survey, 1995. Third National Health and Nutrition Examination Survey, 1988-1991. Selected Laboratory and Mobile Examination Center Data. Version 1, September, 1995.
45. Nestorov I. Whole body pharmacokinetic models. Clinical Pharmacokinetics 2003, 42:883-908.
46. Neville M.C., et al. Studies in human lactation - milk volumes in lactating women during the onset of lactation and full lactation. American Journal of Clinical Nutrition 1988, 48:1375-1386.
47. Neville M.C., et al. Studies in human lactation - milk volume and nutrient composition during weaning and lactogenesis. American Journal of Clinical Nutrition 1991, 54:81-92.
48. Nong A., et al. Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: a case study with toluene. Toxicology and Applied Pharmacology 2006, 214:78-87.
49. Ponnapalli, K.M., 2006. Measuring the contribution of each reproductive age of women for the difference in mean age at last birth and mean age at first birth: a methodological innovation in fertility research. In: Population Association of America (PAA) 2006 Annual Meeting, Los Angeles, CA.
50. Poulin P., Krishnan K. An algorithm for predicting tissue-blood partition-coefficients of organic-chemicals from n-octanol-water partition-coefficient data. Journal of Toxicology and Environmental Health 1995, 46:117-129.
51. Poulin P., Theil F.P. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. Journal of Pharmaceutical Sciences 2002, 91:129-156.
52. Preece M.A., Baines M.J. New family of mathematical-models describing human growth curve. Annals of Human Biology 1978, 5:1-24.
53. Price K., et al. Physiological modeling of age-specific changes in the pharmacokinetics of organic chemicals in children. Journal of Toxicology and Environmental Health - Part A 2003, 66:417-433.
54. R Development Core Team, 2008. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
55. Redding L.E., et al. Population physiologically based pharmacokinetic modeling for the human lactational transfer of PCB-153 with consideration of worldwide human biomonitoring results. Environmental Health Perspectives 2008, 116:1629-1634.
56. Serrano-Trespalacios, P.I. et al., 2002 Ambient, indoor and personal exposure relationships of volatile organic compounds in Mexico City Metropolitan Area. In: 9th International Conference on Indoor Air Quality and Climate (Indoor Air 2002), Monterey, CA, pp. S118-S132.
57. Smith T., et al. Genetic and dietary factors affecting human metabolism of 1,3-butadiene. Chemico-Biological Interactions 2001, 135-136:407-428.
58. Sweeney L.M., et al. Development of a preliminary physiologically based toxicokinetic (PBTK) model for 1,3-butadiene risk assessment. Chemico-Biological Interactions 2001, 135-136:303-322.
59. Tan Y.M., et al. Use of a physiologically based pharmacokinetic model to identify exposures consistent with human biomonitoring data for chloroform. Journal of Toxicology and Environmental Health - Part A - Current Issues 2006, 69:1727-1756.
60. Van der Molen G.W., et al. A generic toxicokinetic model for persistent lipophilic compounds in humans: an application to TCDD. Fundamental and Applied Toxicology 1996, 31:83-94.
61. Verner M.A., et al. A Physiologically based pharmacokinetic model for the assessment of infant exposure to persistent organic pollutants in epidemiologic studies. Environmental Health Perspectives 2009, 117:481-487.
62. von Bertalanffy L. A quantitative theory of organic growth. Human Biology 1938, 10:181-213.
63. Yang F., et al. Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model. Journal of Pharmacokinetics and Pharmacodynamics 2006, 33:485-518.
64. Young J.F., et al. Physiological " constants" for PBPK models for pregnancy. Journal of Toxicology and Environmental Health 1997, 52:385-401.
65. Young J.F., et al. Human Organ/Tissue Growth Algorithms that Include Obese Individuals and Black/White Population Organ Weight Similarities from Autopsy Data. Journal of Toxicology and Environmental Health - Part A - Current Issues 2009, 72:527-540.